Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vera Therapeutics
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
July 01, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
June 11, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 07, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
May 28, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
May 25, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 09, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
April 02, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
March 20, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
February 28, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 02, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
February 01, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
January 29, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
January 29, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
January 25, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
January 08, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
January 08, 2024
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
November 09, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
November 04, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Scheduled to Present at November Investor Conferences
October 30, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting
October 13, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Scheduled to Present at September Investor Conferences
August 31, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
August 10, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
June 17, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN
June 15, 2023
From
Vera Therapeutics
Via
GlobeNewswire
Tickers
VERA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.